RU EN
Get tested

Multi-cancer early detection: a blood test that picks up the signal of early cancer

CA-62 is a serum MCED test that detects stage I–II cancer with 89–94% sensitivity across six carcinoma types, before symptoms appear. The marker reflects tumour growth, not tumour size.

The world’s first multi-cancer (MCED) test system for detecting carcinomas with no restriction on tumour site to be authorised for use by a government authority: Roszdravnadzor certificate No. RZN 2020/9880 of 3 April 2020. Available at Citilab and DNKOM laboratories in 250+ cities across Russia.

Serum CA-62 level

Cut-off — 5,000 U/mL

≤ 5,000reference range for 95% of healthy individuals
> 5,000repeat the test in 4–8 weeks
Schematic, not to scale. An isolated elevation of CA-62 is not a diagnosis — results are interpreted by a physician.

Cancer found early is treated far more successfully

Hypertension or diabetes are kept under control for life. Many cancers found at an early stage, by contrast, are cured completely — as the World Health Organization also notes.

But early cancer does not hurt and does not go away by itself. It has to be looked for, not waited for.

How many people out of 10 live 5 years or more
  • Breast nearly all 3 out of 10
  • Prostate nearly all 4 out of 10
  • Kidney 9 out of 10 2 out of 10
  • Ovary 9 out of 10 3 out of 10
  • Colorectal 9 out of 10 2 out of 10
  • Lung 7 out of 10 1 out of 10

CA-62 detects 89–94% of cancers already at stage I–II — where the chances of cure are highest.

Five-year relative survival compared with people of the same age and sex without cancer, rounded to whole people out of 10; “nearly all” means the same as people without cancer. USA, SEER registry, 2016–2022.

CA-62 at a glance

89–94%

sensitivity already at stage I–II

95%

specificity — 95% of healthy people test within the normal range

6

cancer types with statistically confirmed accuracy — together they account for nearly half of all cancer deaths in Russia*

Accuracy confirmed for six cancer types — nearly half of all cancer deaths

These are the types with enough statistics so far, not the limit of the method. Early detection cases have been described across almost the entire tumour spectrum, including choroidal melanoma. Sarcomas are not detected; tumours with a low cell division rate (low Ki-67 index) are detected later.

* About 47% of cancer deaths in Russia: lung 15.8%, colorectal 14.2%, breast 6.7%, prostate 4.8%, kidney 2.7%, ovary 2.6%. Source: GLOBOCAN, IARC/WHO.

  • breast
  • prostate
  • lung
  • ovarian
  • kidney
  • colorectal

How it works

CA-62 is a signal of rapid cell division, not a product of cell destruction. That is why it works where conventional tumour markers are still silent.

  1. A tumour releases the marker while it grows

    Cancer cells divide and metabolise an order of magnitude more intensively than normal cells. In the process, their membrane proteins with a distinctive N-glycosylation pattern continuously enter the blood — and these are what the test detects.

  2. So the signal is there at early stages

    The marker enters the blood as a result of cell activity, not cell death, and not in proportion to tumour size. Conventional tumour markers grow with tumour volume and often stay normal at early stages.

  3. A repeat test filters out temporary rises

    Rapid cell division also happens without cancer: with inflammation, immune response, recovery from blood loss, pregnancy. Such rises pass, so a result above the cut-off is checked with a repeat test in 4–8 weeks.

Our track record

>10,000

tests performed

850+

medical centres

250+

cities in Russia where the test is available

6

pilot deployments in Russia, Kazakhstan, Canada and the USA

A simple, reliable way to check

Annual check-up

A yearly health check. One test replaces a large number of tumour markers and imaging examinations.

A normal result lowers the probability of aggressive cancer by about 10 times: for people around 55, the estimated negative predictive value is about 99.9%.

Screening programmes

Narrows down risk groups and simplifies cancer detection in screening. Lowers spending on complex diagnostics by reducing the number of patients who need them.

Insurance programmes

Lower costs for diagnosing and treating insured cases.

A technology first developed in Russia

CA-62 is the world’s first multi-cancer (MCED) test system for detecting epithelial carcinomas with no restriction on tumour site to be authorised for use by a government authority (Roszdravnadzor registration certificate No. RZN 2020/9880 of 3 April 2020). Carcinomas account for about 90% of all cancers. High sensitivity at stage I–II has been confirmed in blinded studies at Sechenov University.

Per the instructions for use: an auxiliary in vitro diagnostic method intended to help the physician make a medical decision. Share of carcinomas — per “Malignant neoplasms in Russia in 2024” (P. A. Herzen Moscow Oncology Research Institute).

Registration certificate
No. RZN 2020/9880
North America
Laboratory-developed test (LDT) since 2025

Performed by a CLIA-certified laboratory in Montreal, Canada. LDTs are not cleared or approved by the U.S. Food and Drug Administration.

489patients with stage I–II cancer
141healthy participants

Blinded studies, Sechenov University, 2021–2022. Diagnostic performance established for 6 cancer types.

89–94%sensitivity
95%specificity
Publications and patents

CA-62 versus classic tumour markers

Sensitivity at 95% specificity, early stages, versus apparently healthy controls

Sensitivity of CA-62 and other markers at 95% specificity, by cancer type
Cancer typeMarkerSensitivity
Breast cancerCA-6293%
CA 15-338.5%
Lung cancerCA-6292.5%
CEA39%
CYFRA 21-115%
Prostate cancerCA-6290%
PSA20%
Colorectal cancerCA-6287%
CEA49%
Ovarian cancerCA-62 (> 5,000 U/mL)90%
CA-12556%
Kidney cancerCA-6295%

DNA-based multi-cancer tests in prospective studies

In a prospective study, thousands of people without symptoms give a blood sample and are followed for a year to see what share of all cancers diagnosed the test flagged in advance. This is the closest picture of real-world performance. For tumour-DNA tests, such data have been published:

  • 39.3%Galleri (Grail), PATHFINDER 2, 35,878 participants aged 50+, 2026. For the 12 deadliest cancers, 69.8%; specificity 99.6%.
  • 30.7%Galleri (Grail), NHS-Galleri, randomised trial, 142,250 participants aged 50–77, 2026. For 12 cancer types, 54.7%. The primary goal, fewer stage III–IV cancers, was not met.
  • 27.1%CancerSEEK, DETECT-A, 10,006 women with no history of cancer, 2020; specificity 98.9%.

Why. Tumour DNA enters the blood when cells die, and its amount depends on tumour mass, so early tumours release little. CA-62 reflects how actively cells divide, not tumour size.

In a prospective study of patients with suspected lung cancer on CT, CA-62 was above 5,000 U/mL in 87.5% of early-stage cases. This is a different population, people already suspected of cancer rather than everyone screened, so the figures are not directly comparable.

Sources: PATHFINDER 2, ASCO 2026; NHS-Galleri, ASCO 2026; DETECT-A, Science 2020.

For physicians and clinics

CA-62 is a marker of poorly differentiated cells. It reflects proliferation intensity, which makes it useful both for primary detection and for monitoring patients after treatment.

Target
Membrane proteins with a distinctive N-glycosylation pattern typical of poorly differentiated cells
Method
Competitive immunoassay with a single binding site, measuring the total serum level of these proteins
Scale
Competitive assay: the luminescence signal falls as antigen concentration rises — in the order of 10⁶ at ~1,000 U/mL and hundreds above 7,000 U/mL. Values of 4,500 and 5,500 U/mL differ in signal by about two orders of magnitude, so close-looking numbers are not compared directly; interpretation is threshold-based
Cut-off
5,000 U/mL — upper limit of the reference interval, inclusive; about 95% of clinically healthy individuals fall within it
Spectrum
Accuracy statistically confirmed for 6 carcinoma types; detection cases described for most tumours, including choroidal melanoma. Sarcomas are not detected; low-Ki-67 tumours are detected later — sensitivity follows proliferative activity, not the degree of differentiation
Result
Interpreted by a physician together with clinical, laboratory and imaging data

Questions to the developers and clinical discussion — Telegram chat for physicians t.me/EarlyDiagnosisPractice. Partnerships with clinics and requests for materials: info@oncomarker.ru. Publications and patents

Physicians sectionResult reference

Where to get tested

In Russia, the test is available through laboratory networks in more than 250 cities. Clinics and partners outside Russia — please contact us at info@oncomarker.ru.

from 8,000 RUBin Russia, before laboratory discounts

Interpreting the result

≤ 5,000 U/mLwithin the reference range (found in 95% of clinically healthy individuals)
> 5,000 U/mLrequires a repeat test within 4–8 weeks and assessment together with clinical, laboratory and imaging data

An isolated elevation of CA-62 is not a diagnosis. Results are interpreted by a physician in the context of other clinical findings.

Possible non-cancer causes of elevation

A temporary rise in CA-62 may occur with acute inflammatory and infectious diseases; exacerbations of chronic liver, lung or gastrointestinal disease; allergy, asthma and certain other autoimmune processes; pregnancy and breastfeeding; recent vaccination; active tissue regeneration; administration of immunogenic drugs or cell therapy; acute blood loss and other acute conditions.

Decrease during treatment

In patients with cancer, a drop in the marker below the reference value reflects either a response to treatment or a side effect of drugs that suppress the immune system or blood cell production.

More on the CA-62 normal range and results

Questions about the CA-62 test

For physicians: significance, publications, reference tools

What is the CA-62 tumour marker?

CA-62 is a multi-cancer early detection (MCED) blood test based on a marker of poorly differentiated cells. The test measures the total level of membrane proteins carrying a distinctive N-glycosylation pattern, which enter the bloodstream when cells divide rapidly, including cancer cells. The test system is registered by Roszdravnadzor in Russia, certificate No. RZN 2020/9880.

What is the normal range for CA-62?

Up to and including 5,000 U/mL. Results of 95% of clinically healthy people fall within this range. A result above 5,000 U/mL requires a repeat test within 4–8 weeks and evaluation by a physician together with other findings.

Can I compare two CA-62 results with each other?

Only with a physician. CA-62 is measured by a competitive assay: the more marker in the blood, the weaker the light signal the analyser reads. At around 1,000 U/mL the signal is in the order of a million units; above 7,000 U/mL it is only in the hundreds. So numbers that look close can differ greatly in signal: 4,500 and 5,500 U/mL differ in luminescence by about a hundredfold. A result is assessed against the 5,000 U/mL cut-off, and changes over time are assessed by a physician.

Does an elevated CA-62 mean I have cancer?

No. An isolated elevation of CA-62 is not a diagnosis. The marker responds to any rapid cell division: inflammation and infection, immune response after vaccination, recovery from blood loss, pregnancy. Temporary causes resolve, so the test is repeated in 4–8 weeks. If the level stays high, a physician orders further examination.

Does inflammation raise CA-62?

Not by itself. The marker responds not to inflammatory proteins but to active cell division, such as stem cells producing antibodies and immune cells during an acute process. So a temporary rise is possible with acute inflammation, infection or an exacerbation of a chronic disease. In chronic inflammatory diseases in remission, an elevated level occurs in no more than 5% of cases; in autoimmune diseases it is more common, up to half of cases (in psoriasis only in isolated cases). With cancer the elevation does not resolve on its own, so the test is repeated after 30–60 days and the history is taken into account.

Should CA-62 be part of an annual check-up without symptoms?

Yes. CA-62 is a non-organ-specific signal: it reflects the accumulation of cells with signs of poor differentiation and can point to a process before its location is known. It does not replace organ-specific examinations and tumour markers but complements them — these methods answer different questions. Among apparently healthy people, a result above 5,000 U/mL occurs in about 3% under 40, 5% at 45–60 and 6% over 55; in that case the test is repeated after 30–60 days.

How is CA-62 different from conventional tumour markers (CEA, CA 15-3, PSA)?

The signal of conventional tumour markers depends on tumour size, so they often stay normal at early stages. The CA-62 signal depends on the metabolic activity of tumour cells: an elevated level has been described with tumours as small as 5 mm. That is why CA-62 sensitivity is already high at stage I–II: 89–94% across six carcinoma types, compared with 15–56% for conventional markers in comparative data.

Which cancers does CA-62 detect?

Diagnostic accuracy is statistically confirmed for carcinomas of the breast, prostate, lung, ovary, kidney and colon/rectum, which together account for nearly half of all cancer deaths in Russia. Early detection cases have been described across almost the entire tumour spectrum, including choroidal melanoma. Sarcomas are not detected, and tumours with a low cell division rate (low Ki-67 index) are detected later.

Who should take the CA-62 test?

According to the instructions for use, the test is intended to help a physician decide on further examination. It is used in annual check-ups, screening programmes and to monitor patients during and after treatment. Discuss the test and your result with a physician.

How reliable is a normal result?

A result of up to and including 5,000 U/mL lowers the probability of aggressive cancer by about 10 times. For people around 55 years old, the estimated negative predictive value of the test is about 99.9%. In other words, of 1,000 people that age about 10 have cancer, and in about one of them it may go undetected in the current year.

How much does the CA-62 test cost?

In Russia, from 8,000 RUB at partner laboratories, before discounts. Check the exact price on the laboratory's website.

Where can I take the CA-62 test?

In Russia, at Citilab and DNKOM laboratories in more than 250 cities. Clinics and partners outside Russia can contact us at info@oncomarker.ru.